You are here
Novel Methods for Rapid Detection of Infection Agents and the Severity of Cellular Damage
Award Information
Agency: Department of Defense
Branch: Defense Advanced Research Projects Agency
Contract: N10PC20233
Agency Tracking Number: 08ST1-0060
Amount:
$749,291.00
Phase:
Phase II
Program:
STTR
Solicitation Topic Code:
ST081-003
Solicitation Number:
2008.A
Timeline
Solicitation Year:
2008
Award Year:
2010
Award Start Date (Proposal Award Date):
2010-06-15
Award End Date (Contract End Date):
2012-06-14
Small Business Information
1165 Chess Drive Suite H, Foster City, CA, 94404-
DUNS:
803607154
HUBZone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Principal Investigator
Name: Lulu Zhang
Title: Principal Investigator
Phone: (517) 378-3758
Email: luzhang@diacarta.com
Title: Principal Investigator
Phone: (517) 378-3758
Email: luzhang@diacarta.com
Business Contact
Name: Aiguo Zhang
Title: President, DiaCarta LLC
Phone: (517) 378-3758
Email: azhang@diacarta.com
Title: President, DiaCarta LLC
Phone: (517) 378-3758
Email: azhang@diacarta.com
Research Institution
Name: University of Rochester
Contact: Donna Beyea
Address: 518 Hylan Building
University of Rochester
Rochester, NY, 14627-
Phone: (585) 275-8036
Type: Nonprofit college or university
Contact: Donna Beyea
Address: 518 Hylan Building
University of Rochester
Rochester, NY, 14627-
Phone: (585) 275-8036
Type: Nonprofit college or university
Abstract
Early detection of virulent infectious pathogens is critical to blocking the devastating epidemic spread of the pathogen and the potential harm this could have on our armed forces and general populations. In Phase I, we have utilized the state-of-the-art QuantiGene 2.0 technology to establish an assay for the sensitive quantification of SARS (epidemic spread in 2001) and assessing plasma DNA levels as a measure of the severity of cellular damage induced by a variety of insults, including infectious disease and radiation injury. In this Phase II, we will expand our assay to detect additional pathogens that are currently at epidemic levels worldwide. In addition, we will migrate from a 96-well plate to a chip-based assay platform containing magnetic beads as a reaction surface and portable sample processing/readout device. We will focus on two aims: 1) develop assays for the currently emerging influenza (H1N1) epidemic and tuberculosis; 2) develop a chip-based assay platform and portable device for use as an assay for infectious diseases in resource-limited conditions. The Phase II study will further advance our capability to develop an early detection assay for virulent pathogens and determine the cellular damage caused by all insults using a portable in vitro diagnostic device. * Information listed above is at the time of submission. *